Key result
Bivalirudin-based anticoagulation during primary PCI significantly decreased 1-year all-cause mortality compared with heparin ± glycoprotein IIb/IIIa inhibitors (RR 0.81; 95% CI 0.69-0.94; P=0.008).
Why the study?
Although bivalirudin improves 30-day mortality compared with heparin in primary PCI for STEMI, no meta-analysis had evaluated whether this benefit persists beyond 30 days.
Does a bivalirudin-based anticoagulation strategy reduce 1-year mortality in patients with ST-elevation myocardial infarction undergoing primary PCI compared with heparin ± glycoprotein IIb/IIIa inhibitors?
Meta-Analysis
Does a bivalirudin-based anticoagulation strategy reduce 1-year mortality in patients with ST-elevation myocardial infarction undergoing primary PCI compared with heparin ± glycoprotein IIb/IIIa inhibitors?
Effect estimate: RR 0.81 (95% CI 0.69-0.94)
p-value: p=0.008
A bivalirudin-based anticoagulation strategy during primary PCI for STEMI significantly reduces 1-year all-cause and cardiac mortality compared to heparin-based strategies.
No takes yet. Share an insight, caveat, or question.
Supports bivalirudin preference in STEMI primary PCI; extends meta-analytic evidence for 1-year mortality reduction versus heparin regimens.
Jagadish et al. (2021) conducted a meta-analysis in ST-elevation myocardial infarctions. Bivalirudin vs. Heparin ± glycoprotein IIb/IIIa inhibitors was evaluated on All-cause mortality at 1 year (RR 0.81, 95% CI 0.69-0.94, p=0.008). Bivalirudin-based anticoagulation during primary PCI significantly decreased 1-year all-cause mortality compared with heparin ± glycoprotein IIb/IIIa inhibitors (RR 0.81; 95% CI 0.69-0.94; P=0.008).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: